Business, energy, technology, markets and global industry news from Business News Today

PT886

PharmaDeviceNews PT886
Spevatamig’s FDA Fast Track designation advances Phanes Therapeutics’ development strategy in advanced and metastatic biliary tract cancer as the investigational bispecific antibody moves deeper into clinical evaluation. Representative image.
Pharma & Biotech

Phanes Therapeutics advances CLDN18.2 and CD47 bispecific spevatamig in biliary tract cancer

FDA Fast Track gives spevatamig a faster regulatory path in biliary tract cancer as Phanes advances its Phase 2 and pembrolizumab strategy.

Read More
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026

See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.

Read More
Pharma & Biotech

Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard

Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.

Read More